Pliant Therapeutics
WEBOur highly experienced team of fibrosis and drug development experts are claiming new territory in tissue-specific therapies. Pliant’s broad pipeline includes two clinical stage programs, including the first clinical stage, oral, selective small molecule integrin inhibitor.
Investors & Media - Pliant Therapeutics, Inc.
WEBPliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody against integrin α7β1 targeting muscular dystrophies. In addition to clinical stage programs, Pliant has developed PLN-101325 an anti-integrin mAb of α7β1 currently in preclinical studies targeting muscular dystrophies.
Pliant Therapeutics Announces Positive Data from the INTEGRIS …
WEBPliant's lead product candidate, bexotegrast (PLN-74809), is an oral small molecule dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or …
Pliant Therapeutics Announces FDA Clearance of Investigational …
WEBPliant's lead product candidate, bexotegrast (PLN-74809), is an oral small molecule dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or …
About - Pliant Therapeutics
WEBPliant Therapeutics is a clinical-stage biopharmaceutical company leading the way in developing new treatments for fibrotic diseases. As fibrosis is a complex disease, few available treatments for fibrosis exist today.
Pliant Therapeutics Provides Corporate Update and Reports Fourth ...
WEBPliant is currently conducting Phase 2a trials of bexotegrast in the lead indications of IPF and PSC. Pliant has also developed PLN-1474, a small molecule selective inhibitor of αvß1 for the treatment of nonalcoholic steatohepatitis, or NASH with liver fibrosis.
Pliant Therapeutics Reports Positive Interim Results from Phase 2a …
WEBPliant is currently recruiting for Phase 2a trials of PLN-74809 in the lead indications of IPF and PSC. Pliant has also developed PLN-1474, a small-molecule selective inhibitor of αvß1 for the treatment of nonalcoholic steatohepatitis, or NASH with liver fibrosis, which Pliant has transferred to Novartis pursuant to its development partnership.
Pliant Therapeutics Announces Closing of Upsized Public Offering …
WEBPliant is advancing its discovery and clinical stage portfolio by applying its deep understanding of fibrosis biology, medicinal chemistry, translational medicine and expertise integrin structure and biology.
Pliant Therapeutics Highlights Recent Developments for Lead …
WEBPliant is currently recruiting Phase 2a trials of PLN-74809 in the lead indications of IPF and PSC. Pliant has also developed PLN-1474, a small molecule selective inhibitor of α v ß 1 for the treatment of nonalcoholic steatohepatitis, or NASH with liver fibrosis, which Pliant has transferred to Novartis pursuant to our development partnership.
Pliant Therapeutics Provides Corporate Update and Reports Third …
WEBPliant's lead product candidate, PLN-74809 (bexotegrast), is an oral small molecule dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or …